Inventor
JUHL MARTIN
DK19 patents
Patents
19 patentsUS11707476B2Jul 25, 2023
Catecholamine prodrugs for use in the treatment of parkinson's disease
H LUNDBECK AS12 citations93
US11110110B2Sep 7, 2021
Catecholamine prodrugs for use in the treatment of Parkinson's disease
H LUNDBECK AS15 citations93
US10729710B2Aug 4, 2020
Catecholamine prodrugs for use in the treatment of Parkinson's disease
H LUNDBECK AS21 citations93
US11168056B2Nov 9, 2021
Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
H LUNDBECK AS14 citations92
US11130775B2Sep 28, 2021
Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS14 citations92
US11111263B2Sep 7, 2021
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS15 citations92
US12226428B2Feb 18, 2025
Catecholamine prodrugs for use in the treatment of Parkinson's disease
H LUNDBECK AS6 citations85
US11851456B2Dec 26, 2023
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS9 citations84
US11827665B2Nov 28, 2023
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS8 citations84
US11104697B2Aug 31, 2021
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS14 citations84
US11866410B2Jan 9, 2024
Process for the manufacturing of (6AR,10AR)-7-propyl-6,6A,7,8,9,10,10A,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4AR, 10AR)-1-propyl-1,2,3,4,4A,5,10,10A-octahydro-benzo[G]quinoline-6,7-diol
H LUNDBECK AS8 citations83
US11858954B2Jan 2, 2024
Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS8 citations83
US12479801B2Nov 25, 2025
Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-g]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol
H LUNDBECK AS0 citations61
US12421271B2Sep 23, 2025
Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR, 10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS0 citations61
US12398169B2Aug 26, 2025
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
H LUNDBECK AS0 citations61
US12152029B2Nov 26, 2024
Crystalline forms of a MAGL inhibitor
H LUNDBECK AS0 citations56
US12384765B2Aug 12, 2025
Catecholamine prodrugs for use in the treatment of Parkinson's Disease
H LUNDBECK AS0 citations51
US12319710B2Jun 3, 2025
Catecholamine prodrugs for use in the treatment of Parkinson's diseases
H LUNDBECK AS0 citations51
US12391650B2Aug 19, 2025
Catecholamine prodrugs for use in the treatment of Parkinson's disease
H LUNDBECK AS0 citations50